Dabigatran versus warfarin in patients with atrial fibrillation

New England Journal of Medicine

Volumn 361, Issue 27, 2009, Pages 2673-2674

  Poller, Leon ^a   Jespersen, Joergen ^a   Ibrahim, Saied ^a  

^a European Action on Anticoagulation Central Facility   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; PYRIDINE DERIVATIVE;

BLEEDING; CARDIOVASCULAR RISK; DEATH; DRUG FATALITY; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; LETTER; PRIORITY JOURNAL; STROKE; THROMBOSIS; AGE; CHEMICALLY INDUCED DISORDER; INTERNATIONAL NORMALIZED RATIO; MORTALITY; NOTE;

AGE FACTORS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; EMBOLISM; HEMORRHAGE; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; PYRIDINES; STROKE; WARFARIN;

EID: 74049097539     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Poller L, Keown M, Ibrahim S, et al. An international multi-center randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008;6:93543.
2. van den Besselaar AM, Poller L, Tripodi A. Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy (1999). WHO Tech Rep Ser 1999;889:6493.
3. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl:204S233S.
4. Poller L, Hirsh J. Laboratory monitoring of anticoagulant P59. In: Poller L, Hirsh J, eds. Oral anticoagulants. London: Arnold, 1996:54.